The Unlikely Union of Bard and Bainbridge
Executive Summary
CR Bard bought Bainbridge Sciences three years ago as part of an effort to expand the portfolio of its highly regarded urology franchise into high tech, high margin areas. Proponents saw it as an opportunity to get Bard Urological division moving again. Opponents wondered what the device company wanted in a complex business it didn't know anything about.
You may also be interested in...
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.